Supporting Information

GSH-activatable Camptothecin Prodrug-loaded Gold Nanostar Coated with Hyaluronic Acid for Targeted Breast Cancer Therapy via Multiple Radiosensitization Strategies

Yingke Hou[b,#], Bin Sun[b,#], Rongtian Li[b,d,#], Wei Meng[b], Wenhua Zhang[c], Nuan Jia[d], Ming Chen[e], Jinxiang Chen[b]*, Xiaoyan Tang[a]**

[a.] Department of Chemistry and Materials Engineering, Jiangsu Key Laboratory of Advanced Functional Materials, Changshu Institute of Technology, Changshu 215500, China

[b.] NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China

[c.] College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China

[d.] Southern University of Science and Technology Hospital, Shenzhen 518055, China

[e.] The People' s Hospital of Gaozhou, Gaozhou 525200, China

Emails: chnimike88@163.com (M.C); jxchen@smu.edu.cn (J.X.C); tangxy@cslg.edu.cn (X.Y.T)



Figure S1. The synthetic process of prodrug CPT-SS-FL.



Figure S2. The ^{1}H NMR of **3** in $CDCl_3$.



Figure S3. The ^{1}H NMR of **5** in CD_3OD.



Figure S4. The ^{1}H NMR of CPT-SS-FL in $CDCl_3$.



Figure S5. The ^{13}C NMR of CPT-SS-FL in $CDCl_3$.



Figure S6. The ESI-MS spectra of CPT-SS-FL.



Figure S7. The photograph of the stability of **AS** (A) and (B) **ASH** in water, PBS, DMEM, and DMEM+10% FBS for 12 h.



Figure S8. Energetic contributions of key residues in Topotecan (a)/CPT (b)/CPT-SS-FL (c)—Topo I isomerase complex.



Figure S9. The GSH-mediated disulfide bond cleavage for CPT-SS-FL.



Figure S10. The FL was released from **AS** (CPT-SS-FL = 2.5 μM) at a different time in the presence of GSH.



Figure S11. The hemolytic activity of **ASH**.



Figure S12. The CLSM images of HIF-1α protein expression in tumor tissue after different treatments. (scale bar = 50 μm).



Figure S13. The CLSM images of γ-H2AX protein expression in tumor tissue after different treatments. (scale bar = 50 μm)



Figure S14. The CLSM images of CRT exposure in tumor tissue after different treatments. (scale bar = 50 μm).



Figure S15. The CLSM images of HMGB1 release in tumor tissue after different treatments. (scale bar = 50 μm).